Multiple Cancer/Testis Antigens Are Preferentially Expressed in Hormone-Receptor Negative and High-Grade Breast Cancers

被引:0
|
作者
Chen, Yao-Tseng [1 ]
Ross, Dara S. [1 ]
Chiu, Rita [2 ]
Zhou, Xi K. [3 ]
Chen, Yunn-Yi [4 ]
Lee, Peishan [2 ]
Hoda, Syed A. [1 ]
Simpson, Andrew J. [2 ]
Old, Lloyd J. [2 ]
Caballero, Otavia [2 ]
Neville, A. Munro [2 ]
机构
[1] Cornell Univ, Weill Med Coll, Dept Pathol & Lab Med, New York, NY 10021 USA
[2] Ludwig Inst Canc Res, New York Branch, New York, NY USA
[3] Cornell Univ, Weill Med Coll, Dept Publ Hlth, New York, NY 10021 USA
[4] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA
来源
PLOS ONE | 2011年 / 6卷 / 03期
关键词
T-CELL RESPONSES; NY-ESO-1; EXPRESSION; PROTEIN EXPRESSION; ANTIBODY; IMMUNOGENICITY; IDENTIFICATION; CARCINOMA; FAMILY; GENES; CT45;
D O I
10.1371/journal.pone.0017876
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Cancer/testis (CT) antigens are protein antigens normally expressed only in germ cells of testis, and yet are expressed in a proportion of a wide variety of human cancers. CT antigens can elicit spontaneous immune responses in cancer patients with CT-positive cancers, and CT antigen-based therapeutic cancer vaccine trials are ongoing for "CT-rich" tumors. Although some previous studies found breast cancer to be "CT-poor", our recent analysis identified increased CT mRNA transcripts in the ER-negative subset of breast cancer. Methodology/Principal Findings: In this study, we performed a comprehensive immunohistochemical study to investigate the protein expression of eight CT genes in 454 invasive ductal carcinomas, including 225 ER/PR/HER2-negative (triple-negative) carcinomas. We found significantly more frequent expression of all eight CT antigens in ER-negative cancers, and five of them-MAGEA, CT7, NY-ESO-1, CT10 and CT45, were expressed in 12-24% of ER-negative cancers, versus 2-6% of ER-positive cancers (p < 0.001 to 0.003). In comparison, GAGE, SAGE1 and NXF2 were only expressed in 3-5% of ER-negative and 0-2% of ER-positive cancers. ER-negative cancers were also more likely to simultaneously co-express multiple CT antigens, with 27% (34/125) of ER-negative, CT-positive tumors expressing three or more CT antigens. HER2 status had no consistent effect on CT expression, and triple-negative carcinomas showed similar frequencies of MAGEA and NY-ESO-1 expression as ER-negative/HER2-positive carcinomas. More frequent CT expression was also found in tumors with higher nuclear grade (p < 0.001 to p = 0.01) and larger in size (> 2 cm). Conclusions/Significance: CT antigens are preferentially expressed in hormone receptor-negative and high-grade breast cancer. Considering the limited treatment options for ER/PR/HER2 triple-negative breast cancer, the potential of CT-based immunotherapy should be explored.
引用
收藏
页数:9
相关论文
共 25 条
  • [11] New Challenges in the Differential Diagnosis of High-Grade Triple-Negative Breast Cancer and Serous Carcinoma
    Puzyrenko, Andrii
    Cortina, Chandler S.
    Jorns, Julie M.
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2022, 30 (07) : 728 - 733
  • [12] Histological Features and Tissue Microarray Taxonomy of Nigerian Breast Cancer Reveal Predominance of the High-Grade Triple-Negative Phenotype
    Titloye, N. A.
    Foster, A.
    Omoniyi-Esan, G. O.
    Komolafe, A. O.
    Daramola, A. O.
    Adeoye, O. A.
    Adisa, A. O.
    Manoharan, A.
    Pathak, D.
    D'Cruz, M. N.
    Alizadeh, Y.
    Lewis, P. D.
    Shaaban, A. M.
    PATHOBIOLOGY, 2016, 83 (01) : 24 - 32
  • [13] Epigenetic silencing of CREB3L1 by DNA methylation is associated with high-grade metastatic breast cancers with poor prognosis and is prevalent in triple negative breast cancers
    Ward, Alison K.
    Mellor, Paul
    Smith, Shari E.
    Kendall, Stephanie
    Just, Natasha A.
    Vizeacoumar, Frederick S.
    Sarker, Sabuj
    Phillips, Zoe
    Alvi, Riaz
    Saxena, Anurag
    Vizeacoumar, Franco J.
    Carlsen, Svein A.
    Anderson, Deborah H.
    BREAST CANCER RESEARCH, 2016, 18
  • [14] COX2 expression in high-grade breast cancer: evidence for prognostic significance in the subset of triple-negative breast cancer patients
    Chikman, Bar
    Vasyanovich, Sergey
    Lavy, Ron
    Habler, Liliana
    Tolstov, Gleb
    Kapiev, Andronik
    Halevy, Ariel
    Sandbank, Judith
    MEDICAL ONCOLOGY, 2014, 31 (06)
  • [15] Expression of MAGE-A3/6 in Primary Breast Cancer is Associated With Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival
    Ayyoub, Maha
    Scarlata, Clara-Maria
    Hamai, Ahmed
    Pignon, Pascale
    Valmori, Danila
    JOURNAL OF IMMUNOTHERAPY, 2014, 37 (02) : 73 - 76
  • [16] Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer
    Lonning, Per E.
    Nikolaienko, Oleksii
    Pan, Kathy
    Kurian, Allison W.
    Eikesdal, Hans P.
    Pettinger, Mary
    Anderson, Garnet L.
    Prentice, Ross L.
    Chlebowski, Rowan T.
    Knappskog, Stian
    JAMA ONCOLOGY, 2022, 8 (11) : 1579 - 1587
  • [17] Constitutional BRCA1 and MGMT Methylation Are Significant Risk Factors for Triple-Negative Breast Cancer and High-Grade Serous Ovarian Cancer in Saudi Women
    Al-Moghrabi, Nisreen
    Al-Showimi, Maram
    Alqahtani, Amal
    Almalik, Osama
    Alhusaini, Hamed
    Almalki, Ghdah
    Saad, Ajawhara
    Alsunayi, Elaf
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [18] Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma
    Kakimoto, Takuya
    Matsumine, Akihiko
    Kageyama, Shinichi
    Asanuma, Kunihiro
    Matsubara, Takao
    Nakamura, Tomoki
    Iino, Takahiro
    Ikeda, Hiroaki
    Shiku, Hiroshi
    Sudo, Akihiro
    ONCOLOGY LETTERS, 2019, 17 (04) : 3937 - 3943
  • [19] Immune environment of high-TIL breast cancer: triple negative and hormone receptor positive HER2 negative
    Shin, Su-Jin
    Park, Inho
    Go, Heounjeong
    Ko, Jiwon
    Lee, Yangkyu
    Kim, Jee Hung
    Ahn, Sung Gwe
    Jeong, Joon
    Bae, Soong June
    Cha, Yoon Jin
    NPJ BREAST CANCER, 2024, 10 (01)
  • [20] Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy
    Cordoba, Octavi
    Llurba, Elisa
    Cortes, Javier
    Dolors Sabadell, M.
    Luis Lirola, Jose
    Ferrer, Queralt
    Xercavins, Jordi
    TUMORI JOURNAL, 2010, 96 (04): : 629 - 632